In 2009, Rochester researchers reported in the New England Journal of Medicine that cardiac resynchronization therapy with defibrillator (CRT-D therapy) reduced heart failure in patients with mild forms of the disease. The trial, known as MADIT-CRT, led the FDA in 2010 to extend the approval of CRT-D therapy to patients with mild heart failure and left bundle branch block, a condition that results in disorganized electrical activity throughout the heart. The device was originally approved to treat patients with severe heart failure.
The researchers, led by Arthur J. Moss, M.D., professor of Cardiology, are back in the New England Journal of Medicine this week with the results of the MADIT-CRT long-term follow-up study. Also presented at the American College of Cardiology’s 63rd Annual Scientific Session, the study shows for the first time that CRT-D therapy saves the lives of mild heart failure patients over the long term.
Read more about the study here.
Emily Boynton |
| 0 comments